Natural Squelch spray eliminates odors on skin, hair, clothes
DELRAY BEACH, Fla. — A new all-natural spray promises to not only cover up unwanted smells, but also eliminate them at the source, the company stated this week.
Squelch is an all-natural, non-toxic spray that is odorless. It is safe to use on skin, hair, clothes or any other source that may trap odors. Squelch also is hypoallergenic, does not stain or fade clothes and is environmentally friendly.
According to the company, odors can come from a variety of sources. Virtually all of these sources have common carbon molecule bonds that can cause odors. Squelch works by breaking apart these carbon bonds to eliminate the source of the odor, not just mask it, with its OdorBreak Technology.
Squelch is made with water, vegetable-based fatty acid, soybean oil, corn oil, sodium lauryl sulfate and other natural extracts. It comes in a diminutive, cylindrical tube ideal for portable use after the gym or work, or for use in the car and on the go.
Squelch will soon be available at retailers nationwide and is currently available on the company’s website. It can be purchased individually or in quantities of three, six and 12. Squelch is made in the United States.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Actavis seeks FDA approval for contraceptive patch
PARSIPPANY, N.J. — The Food and Drug Administration will review an experimental contraceptive patch made by Actavis, the drug maker said Tuesday.
Actavis said the FDA accepted for review its application for norethindrone transdermal delivery system. The patch, which does not yet have a brand name, is designed to provide continuous delivery of norethindrone during a once-weekly, seven-day dosing regimen.
The company said once-weekly dosing with the patch may improve compliance and convenience in progestin-only contraceptive users and provide more consistent average levels of norethindrone in the plasma than pills.
Actavis issues regulatory filing to comply with Irish company-takeover rules
PARSIPPANY, N.J. — Actavis is continuing to pursue a plan to buy Irish drug maker Warner Chilcott, as the U.S.-based company announced Tuesday its total number of shares and share-purchase options in order to comply with Ireland’s merger-and-acquisition rules.
Actavis listed about 133.3 million ordinary shares, 1.5 billion restricted shares and 1.26 options to purchase ordinary shares.
The company, which is the world’s third-largest generic drug maker, said Friday that it was in talks to buy Warner Chilcott, but that no agreement had been reached and that it wouldn’t issue further comment about the matter.
Last month, a proposal by Canadian drug maker Valeant Pharmaceuticals International to buy Actavis for more than $13 billion was put off when the two companies failed to reach an agreement.
In other news, Actavis said it canceled its presentation at the Bank of America Merrill Lynch Healthcare Conference, which had been scheduled to take place Tuesday in Las Vegas.